Related Experiment Video
Updated: Sep 17, 2026
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
[Experimental study of therapy effects of anti -VEGF antibody on osteosarcoma]
Yingjia Li1, Dong Wang, Fengxun Gao
1Department of Ultrasound Diagnosis, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Objective:
To investigate the effect of anti-VEGF antibody on angiogenesis induced by osteosarcoma OS-732 cell line and tumor growth.
Methods:
With a tumor model on the chick embryo chorioallantoic membrane (CAM), the inhibition of angiogenesis and tumor growth by anti-VEGF antibody were observed under a stero-microscope and a light microscope. Furthermore, the proliferation and apoptosis in tumor cells and endothelial cells (EC) were studied by TdT-mediated duTP nick and labeling (TUNEL) and immunohistochemical staining using proliferating cell nuclear antigen (PCNA) monoclonal antibody.
Results:
VEGF polyclonal antibody administration in tumor-bearing chick embryo resulted in growth arrest of xenografts and a markedly reduction in the new capillaries which converged upon the tumor. The tumor cell apoptotic index was higher in the anti-VEGF antibody treated group than the negative control group, but the proliferation index was not significantly different between them. At the same time, increased apoptosis and decreased proliferation in EC were also noted.
Conclusion:
VEGF polyclonal antibody is able to inhibit the angiogenesis induced by OS-732 obviously, probably by the mechanism of inhibition of EC proliferation and promotion of their apoptosis, furtherly, which may contribute to the apoptosis of tumor cells and result in suppression of tumor growth.
Insights
Anti-vascular endothelial growth factor (VEGF) antibody treatment significantly reduced osteosarcoma tumor growth and angiogenesis in a chick embryo model. This suggests anti-VEGF therapy can inhibit tumor development by affecting endothelial cell proliferation and apoptosis.
Area of Science:
- Oncology
- Vascular Biology
- Immunotherapy
Context:
- Osteosarcoma (OS) is a primary bone malignancy.
- Tumor growth relies on angiogenesis, the formation of new blood vessels.
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis.
Purpose:
- To evaluate the efficacy of an anti-VEGF antibody in inhibiting angiogenesis and tumor growth induced by the OS-732 osteosarcoma cell line.
- To investigate the effects of anti-VEGF antibody on tumor cell and endothelial cell (EC) proliferation and apoptosis.
Summary:
- A chick embryo chorioallantoic membrane (CAM) tumor model was utilized to assess anti-VEGF antibody effects.
- Administration of VEGF polyclonal antibody led to xenograft growth arrest and reduced tumor-associated neovascularization.
- While tumor cell apoptosis increased, proliferation remained unchanged; however, EC apoptosis increased and proliferation decreased.
Impact:
- Anti-VEGF antibody therapy demonstrates significant potential in suppressing osteosarcoma growth.
- The mechanism involves inhibiting EC proliferation and promoting EC apoptosis, which subsequently impacts tumor cell apoptosis and overall tumor suppression.
- This study provides a basis for exploring anti-VEGF strategies in osteosarcoma treatment.
